Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
British journal of cancer 2011 Feb 104 (4): 605-12.
Kim K-p, Jang G, Hong Y S, Lim H-S, Bae K-s, Kim H-S, Lee S S, Shin J-G, Lee J-L, Ryu M-H, Chang H-M, Kang Y-K, Kim T
A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e15023.
Choi Y, Kim T, Lee S, Lee J, Chang H, Kim H, Shin J, Lee J, Kang